FEDERAL COURT OF AUSTRALIA
Pfizer Overseas Pharmaceuticals v Eli Lilly and Company
[2005] FCAFC 224PATENTS – validity – construction – lack of inventive step – novelty – fair basis – sufficiency of description of invention – disclosure of best method of invention – date of assessment – false suggestion – patent for treatment of erectile dysfunction – common general knowledge at priority date – relevant prior art – use of evidence of overseas witnesses
Patents Act 1990 (Cth) s 18(1), s 40, s 7, s 138
Eli Lilly and Company v Pfizer Overseas Pharmaceuticals (2005) 218 ALR 408 cited
Bristol-Myers Squibb Company v FH Faulding & Co Limited (2000) 97 FCR 524 applied
Canadian General Electric Co Limited v Fada Radio Limited [1930] AC 97 cited
Hill & Evans (1862) 4 De G F & J 288; 45 ER 1195 cited
Aktiebolaget Hassle v Alphapharm Pty Ltd (200r) 212 CLR 411 applied
Lockwood Security Products Pty Ltd v Doric Products Pty Ltd (2004) 212 ALR 1 applied
Martin v Scribal Pty Ltd (1954) 92 CLR 17 applied
Welch Perrin & Co Pty Ltd v Worrel (1961) 106 CLR 588 cited
Interlego AG v Toltoys Pty ltd (1972) 130 CLR 461 applied
Décor Corp Pty Ltd v Dart Industries Inc (1988) 13 IPR 385 cited
Nesbit Evans Group Australia Pty Ltd v Impro Ltd (1997) 39 IPR 56 cited
Kimberly-Clark Australia Pty Ltd v Arico Trading International Pty Ltd (2001) 207 CLR 1 cited
Catnic Components Ltd v Hill & Smith Ltd [1982] RPC 183 cited
CCOM Pty Ltd v Jiejing Pty Ltd (1994) 122 ALR 417 cited
Olin Corporation v Super Cartridge Co Pty Ltd (1977) 180 CLR 236 cited
Société Des Usines Chimiques RhônePoulenc v Commissioner of Patents (1958) 81 ALR 79 cited
Rehm Pty Ltd v Websters Security Systems (International) Pty Ltd (1988) 81 ALR cited
Minnesota Mining and Manufacturing Co v Beiersdorf (Australia) Ltd (1980) 144 CLR 253 cited
WR Grace v Asahi Kasei (1993) AIPC 90-974 cited
Firebelt Pty Ltd v Brambles Pty Ltd (2002) 188 ALR 280 cited
Tidy Tea Ltd v Unilever Australia Ltd (1995) 32 IPR 405 cited
Wellcome Foundation Ltd v VR Laboratories (Aust) Pty Ltd (1981) 148 CLR 262 cited
Olin Mathieson Chemical Corporation v Biorex Laboratories Ltd [1970] RPC 157 followed
Meyers Taylor Pty Ltd v Viccar Industries Ltd (1977) 137 CLR 228 cited
Flour Oxidizing Co Ltd v Carr & Co Ltd (1908) 25 RPC 428 cited
General Tire & Rubber Co v Firestone Tyre and Rubber Co Ltd [1972] RCP 457 cited
Imperial Chemical Industries Pty Ltd v Commissioner of Patents (2004) 213 ALR 399 cited
AMP Inc v Utilux Pty Ltd (1971) 45 ALJR 123 cited
British Dynamite Co v Krebs [1879] 13 RPC 190 cited
Esber v The Commonwealth (1992) 174 CLR 430 cited
Frederikshavn Vaerft A/S v Stena Rederi Aktiebolag (2002) 124 FCR 243 cited
Rescare Limited v Anaesthetic Supplies Pty Ltd (1992) 111 ALR 205 discussed
C Van Der Lely NV v Ruston’s…
Keep reading for free
Create a free CaseChat account to read Pfizer Overseas Pharmaceuticals v Eli Lilly and Company and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2005] FCAFC 224
- Decision Date
CaseChat Overview and Summary
The primary legal issue before the court was whether claim 10 of Pfizer's patent was valid. The court had to determine if the patent specification sufficiently disclosed the invention, if the invention was obvious, and if claim 10 was fairly based on the specification. The court also had to consider whether the patent disclosed a false suggestion and if it complied with the best method requirement.
The court found that Pfizer had successfully demonstrated error in the primary judge's finding regarding the lack of inventive step. However, it upheld the primary judge's finding that claim 10 was not fairly based on the specification. The court concluded that claim 10 was invalid due to the lack of fair basis and dismissed the appeal. The court ruled that each party should bear its own costs of the appeal due to the distribution of success and failure.
The court's decision was that the appeal be dismissed and that the parties bear their own costs of the appeal. This outcome ensures that Pfizer's patent claim 10 remains invalid due to the lack of fair basis in the specification.
Orders
Orders of the court
1. The appeal be dismissed.
2. The parties bear their own costs of the appeal.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.